Infected Blood Inquiry
CompletedExamining how thousands of NHS patients were infected with HIV and Hepatitis C through contaminated blood products in the 1970s and 1980s. Found the scandal could largely have been avoided and victims were failed by the NHS, government, and blood services. As of 7 April 2026, the Infected Blood Compensation Authority (IBCA) had made 3,273 offers of compensation totalling over £2.6bn, with 3,161 accepted — in addition to £1.4bn already paid in interim payments; IBCA had contacted 3,942 people and 3,754 had started the claim process. On 14 April 2026 the Government published its response to consultation on proposed changes to the Scheme (CP 1565), announcing approximately £1bn in additional compensation payments on top of the £11.8bn allocated in the 2024 Autumn Budget, with regulations to follow later in 2026.
Parliamentary Activity 385 Click to expand
Sarah Green (Liberal Democrat)
Baroness Anderson of Stoke-on-Trent (Labour)
Nick Thomas-Symonds (Labour)
Reports (4) Click to expand
| Title | Volume | Publication Date | Tracked recs | Links |
|---|---|---|---|---|
| Additional Report on Compensation | Additional | 09 Jul 2025 | 26 | |
| Infected Blood Inquiry Final Report | Final | 20 May 2024 | 58 | |
| First Interim Report | Interim 1 | 29 Jul 2022 | 1 | |
| Second Interim Report | Interim 2 | 05 Apr 2023 | 18 |
Timeline (10) Click to expand
Sir Brian Langstaff appointed as Chair.
Public hearings commenced.
Second interim report with further compensation recommendations.
Infected Blood Compensation Scheme formally established.
First compensation payments made to eligible infected persons.
Costs Click to expand
Cost Breakdown (to Mar 2025)
Cost History
Recommendations (28)
Individual Duty of Candour for Leaders
- The Public Office (Accountability) Bill 2024-26 was introduced on 16 September 2025 and completed public bill committee scrutiny in December 2025, creating a statutory duty of candour for public authorities and public servants (UK Parliament, 2025-2026).
- The Bill's report stage was postponed in January 2026, and the Bill remained before the House of Commons as of March 2026 (UK Parliament, January 2026).
- No legislation extending the statutory duty of candour to individuals in NHS leadership positions had been enacted as of March 2026.
Leadership Accountability for Safety
- No published secondary legislation requiring individuals in NHS leadership positions to record, consider, and respond to concerns about healthcare provision has been identified to March 2026.
Organisational Culture Change
- The Scottish Government stated that it had responded to reviews about raising concerns in the workplace and was implementing associated recommendations (Government Response to the Infected Blood Inquiry, Cabinet Office, December 2024).
- No independent assessment of progress in addressing the culture of defensiveness in healthcare leadership has been identified to March 2026.
Civil Service Statutory Duty of Candour
- The Public Office (Accountability) Bill 2024-26 was introduced in the House of Commons on 16 September 2025 and completed public bill committee scrutiny in December 2025 (UK Parliament, 2025-2026).
- The Bill's report stage and third reading were postponed in January 2026 for further amendments on national security grounds, and the Bill remained before the House of Commons as of March 2026 (UK Parliament, January 2026).
- The Ministerial Code was updated on 6 November 2024, emphasising openness and candour (Government Response to the Infected Blood Inquiry, Cabinet Office, December 2024).
- The Bill had not been enacted as of March 2026.
Monitoring Non-Statutory Duties
- The Public Office (Accountability) Bill 2024-26 was introduced on 16 September 2025, creating duties for public authorities and public servants including civil servants. The Bill completed public bill committee scrutiny in December 2025 but its report stage was postponed in January 2026 (UK Parliament, 2025-2026).
- The Bill remained before the House of Commons as of March 2026 and had not been enacted (UK Parliament, January 2026).
- No specific statutory duty of accountability on senior civil servants for the candour and completeness of advice had been enacted as of March 2026.
Ministerial Duty of Candour
The Government should consider the extent to which Ministers should be subject to a duty beyond their current duty to Parliament under the Ministerial Code.
- The Ministerial Code was reissued on 6 November 2024 emphasising transparency and accountability (Government Response to the Infected Blood Inquiry, Cabinet Office, December 2024).
- The Scottish First Minister announced changes to the Scottish Ministerial Code strengthening transparency and accountability, including enabling Independent Advisers to launch their own investigations (Government Response to the Infected Blood Inquiry, Cabinet Office, December 2024).
- No statutory duty beyond the Ministerial Code had been enacted as of March 2026.
Specialist Hepatology Centre Access
All patients who have contracted hepatitis via a blood transfusion or blood products should receive the following care:
Those who have fibrosis should receive the same care
- The Government stated in December 2024 that it accepted this recommendation and that the audit of hepatology practices would cover patients with fibrosis (Government Response to the Infected Blood Inquiry, Cabinet Office, December 2024).
- The Scottish Government stated it was seeking clinical advice on monitoring for fibrosis cases (Government Response to the Infected Blood Inquiry, Cabinet Office, December 2024).
- No published guidance on care standards for transfusion-acquired hepatitis patients with fibrosis has been identified to March 2026.
Consultant Hepatologist Access
- The Government stated in December 2024 that it accepted this recommendation and that consultant hepatologist oversight would be provided for all patients where practicable (Government Response to the Infected Blood Inquiry, Cabinet Office, December 2024).
- No published guidance requiring consultant hepatologist appointments for transfusion-acquired hepatitis C patients has been identified to March 2026.
Transfusion Committees and Tranexamic Acid - England
- The Government stated in December 2024 that a four-nation working group had been established to consider an "opt out" approach requiring documented reasoning when tranexamic acid is not used in surgical checklists (Government Response to the Infected Blood Inquiry, Cabinet Office, December 2024).
- The Centre for Perioperative Care was being engaged for provider guidance, with communication activities to support implementation (Government Response to the Infected Blood Inquiry, Cabinet Office, December 2024).
- No published guidance mandating tranexamic acid on every hospital surgical checklist has been identified to March 2026.
Transfusion Laboratory Staffing
Transfusion laboratories:
Transfusion laboratories should be staffed (and resourced) adequately to meet the requirements of their functions.
- The Government stated in December 2024 that work was ongoing to determine the current status of transfusion staffing, reviewing best practice from other areas including nursing, and developing an evidence base to inform minimum staffing standards (Government Response to the Infected Blood Inquiry, Cabinet Office, December 2024).
- No published assessment of transfusion laboratory staffing adequacy has been identified to March 2026.
Training in Transfusion Medicine
- The Government stated in December 2024 that a stakeholder group, including professional and statutory bodies, was working to review and propose educational and training requirements for transfusion medicine (Government Response to the Infected Blood Inquiry, Cabinet Office, December 2024).
- No published updated training standards for transfusion medicine have been identified to March 2026.
Implementing SHOT Reports
- The Government stated in December 2024 that work was underway to develop governance practices for the implementation of SHOT recommendations, with consideration given to standardisation and local needs (Government Response to the Infected Blood Inquiry, Cabinet Office, December 2024).
- No published mechanism mandating implementation and monitoring of SHOT recommendations across all NHS organisations has been identified to March 2026.
Blood Tracking Systems Funding
Establishing the outcome of every transfusion:
That funding for the provision of enhanced electronic clinical systems in relation to blood transfusion be regarded as a priority across the UK.
- No published prioritisation of funding for electronic clinical systems specifically for blood transfusion has been identified to March 2026.
Thalassaemia Society Support
Particular consideration be given, together with the UK Thalassaemia Society and the Sickle Cell Society, to how the needs of patients with thalassaemia or sickle cell disease can best holistically be addressed.
- No published outcome from specific consultation with the UK Thalassaemia Society and Sickle Cell Society on holistic needs has been identified to March 2026.
Ministerial Power to Call Inquiries
That a minister should retain the power to call an inquiry as the minister sees fit, in accordance with the Inquiries Act 2005 – but where a minister does not choose to do so, then:
- No published proposals for amending the mechanism by which public inquiries may be called have been identified to March 2026.
Parliamentary Referral to PACAC
If there is sufficient support from within Parliament for there to be an inquiry, the question whether there should be one should be referred to the Public Administration and Constitutional Affairs Committee (PACAC) for it to consider the question.
- No published decision by Parliament on PACAC's role in assessing whether public inquiries should be called has been identified to March 2026.
PACAC Recommendation Power
- No published decision by Parliament or PACAC on this recommendation has been identified to March 2026.
Ministerial Reasons for Disagreement
If the minister disagrees with the recommendation, they must set out in detail and publish reasons for this disagreement which are sufficient to satisfy PACAC that the matter has been carefully and properly considered.
- No published mechanism requiring ministerial publication of reasons for disagreeing with inquiry recommendations has been identified to March 2026.
PACAC Oversight of Implementation
The Public Administration and Constitutional Affairs Committee (“PACAC”) should review both the progress towards responding to the Inquiry’s recommendations and, to the extent that they are accepted, implementing those recommendations.
- No published decision by PACAC to take up a review role for the Infected Blood Inquiry's implementation progress has been identified to March 2026.
PACAC Role for Future Inquiries
PACAC should accept the role in respect of any future statutory inquiry of reviewing the government’s timetable for consideration of recommendations, and of its progress towards implementation of that inquiry’s recommendations.
- No published decision by PACAC to accept this standing role for future statutory inquiries has been identified to March 2026.
Interferon Treatment Impacts
People infected with Hepatitis B or C who have received a course of treatment with or based on interferon should be recognised as entitled to core awards at Level 3.
- A consultation on proposed changes to the infected blood compensation scheme was opened on 24 November 2025, covering the interferon treatment severity band (Consultation: Proposed Changes to the Infected Blood Compensation Scheme, Cabinet Office, November 2025).
Special Category Mechanism
- A consultation on proposed changes to the infected blood compensation scheme was opened on 24 November 2025, covering this award (Consultation: Proposed Changes to the Infected Blood Compensation Scheme, Cabinet Office, November 2025).
Severe Psychological Harm
- A consultation on proposed changes to the infected blood compensation scheme was opened on 24 November 2025, covering evidence standards for psychological harm (Consultation: Proposed Changes to the Infected Blood Compensation Scheme, Cabinet Office, November 2025).
Financial Loss and Care
"x" be removed from the equation set out in Regulation 7.
- A consultation on proposed changes to the infected blood compensation scheme was opened on 24 November 2025 (Consultation: Proposed Changes to the Infected Blood Compensation Scheme, Cabinet Office, November 2025).
Exceptional Loss Evidence
- A consultation on proposed changes to the infected blood compensation scheme was opened on 24 November 2025 (Consultation: Proposed Changes to the Infected Blood Compensation Scheme, Cabinet Office, November 2025).
Unethical Research Award
Where there is evidence that an individual was the victim of unethical research practices IBCA should be authorised to make an unethical research practices award to that individual.
- A consultation on proposed changes to the infected blood compensation scheme was opened on 24 November 2025, covering the unethical research practices award (Consultation: Proposed Changes to the Infected Blood Compensation Scheme, Cabinet Office, November 2025).
Wider Definition of Unethical Research
When considering the evidence IBCA applies the wider definition of research explained in the Infected Blood Inquiry Additional Report chapter on Unethical Research.
- A consultation on proposed changes to the infected blood compensation scheme was opened on 24 November 2025 (Consultation: Proposed Changes to the Infected Blood Compensation Scheme, Cabinet Office, November 2025).
Supplementary Route for Affected Persons
- A consultation on proposed changes to the infected blood compensation scheme was opened on 24 November 2025, covering the supplementary route for affected persons (Consultation: Proposed Changes to the Infected Blood Compensation Scheme, Cabinet Office, November 2025).